Novo Nordisk A/S revealed encouraging efficacy data for a novel oral obesity medicine during a capital market day on 7 March, intriguing investors who are aware the company will need to deliver next-generation advances in obesity to maintain its leadership position in the competitive therapeutic area.
Key Takeaways
- Novo Nordisk revealed encouraging efficacy data for a novel oral obesity medicine amycretin during a capital market day.
Amycretin, which is a co-agonist of the GLP-1 and amylin receptors, could be a complementary mode of action to Novo...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?